usstocks Shenwan Hongyuan

CSI Intelligent Financial News Xinhua Pharmaceutical (000756) disclosed its first quarter report for 2024 on April 26. In the first quarter of 2024, the company achieved total operating income of 2.475 billion yuan, a year-on-year decrease of 6.25%; net profit attributable to the parent company was 142 million yuan, a year-on-year decrease of 6.41%; non-net profit after deduction was 138 million yuan, a year-on-year decrease of 6.41%; Net cash flow was 38.0634 million yuan, compared with -184 million yuan in the same period last year; during the reporting period, Xinhua Pharmaceutical\’s basic earnings per share was 0.21 yuan, and the weighted average return on net assets was 3.04%.